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Abstract
Background: Explanting infected cardiac implantable electronic devices (CIEDs) and ex-
tracting their associated leads can be performed percutaneously (EP) or via open-thoracotomy 
(OR) approach. In this study, we examined the characteristics and outcomes of infected CIED 
patients undergoing EP vs. OR extraction procedures.
Methods: All patients (EP: n = 329 and OR: n = 24) who received lead extraction in the 
presence of an infected CIED from 2005 to 2010 at the University of Pittsburgh Medical Cen-
ter were included in this study. Demographic and clinical characteristics were obtained from 
the electronic medical records. The Charlson comorbidity index (CCI) was used to adjust for 
severity of co-morbid conditions.
Results: Compared to the EP group, OR patients were more likely to have positive blood cul-
tures, larger vegetations, and worse CCI scores. They also had higher total mortality rates at  
1 (p = 0.036), 6 (p = 0.020), and 12 months (p = 0.012) after the procedure. One-year survival 
after lead extractions was significantly better for the EP compared to the OR group (p = 0.002) 
even after adjusting for other comorbid illnesses (HR = 2.6, p = 0.010) in a Cox regression model.
Conclusions: Infected CIED patients undergoing open-chest lead extraction are sicker and 
have higher mortality rates compared to those undergoing percutaneous extraction. Randomi-
zed, prospective data are needed to determine whether the procedural strategy for lead extraction 
accounts in part for the difference in outcome. (Cardiol J 2015; 22, 1: 68–74)
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Introduction
Multicenter, randomized studies have con-
sistently demonstrated the value of implantable 
cardioverter-defibrillators in reducing mortality 
in patients with chronic heart failure and low left 
ventricular ejection fraction as well as in patient 
with spontaneous or inducible ventricular arrhyth-
mias [1–3]. This has led to a dramatic expansion of 
cardiac implantable electronic devices (CIEDs) in-
dications [4, 5]. As more patients received CIEDs, 
the number of complications associated with these 
procedures has increased [6] including CIED infec-
tions which are rising faster than implantation rates 
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[7–9] and which necessitate complete removal of 
infected CIEDs [10–13]. Traditionally, lead extra-
ction in patients with large vegetations has been 
performed using open thoracotomy (OR), instead 
of percutaneous (EP) techniques, in order to mi-
nimize the risk of embolization [14, 15]. Recently, 
however, several studies have shown that lead 
extraction in patients with infected leads and large 
vegetations can be safely done via EP techniques 
[16–18]. Furthermore, OR may be associated with 
higher rates of significant adverse events that can 
affect mortality [12]. We therefore examined the 
outcome of patients undergoing lead extraction 
for infectious indications by OR or EP techniques, 
focusing on total mortality after the procedure.
Methods
All research methods for this study were 
approved by the University of Pittsburgh Internal 
Review Board. All patients (n = 353) who recei-
ved lead extraction in the presence of an infected 
CIED at one of the hospitals of the University of 
Pittsburgh Medical Center from January 2005 to 
December 2010 were included in this study. De-
tailed demographic and clinical characteristics for 
all the patients were obtained from the electronic 
medical record. Procedural details were retrieved 
from the electrophysiology and cardiothoracic 
surgery operative notes.
Device infections were defined by the treating 
physician using clinical symptoms of infection such 
as fever, swelling, redness, pain, exposure of the 
device or leads at the device implantation site, or 
positive blood cultures. Using the Duke’s criteria 
for endocarditis, presence, size, and location of 
vegetations were documented by echocardiogra-
phy. Patients were selected to undergo open-chest 
vs. closed-chest lead extraction after discussion 
consensus agreement between the treating elec-
trophysiologist and the cardiothoracic surgeon. In 
these discussions, the risk of open-chest surgery 
was weighed against the risk of embolization of 
large vegetations during closed-chest surgery. If the 
patient required additional surgery including valve 
repair or coronary artery bypass grafting, the deci-
sion naturally favored the open surgery approach.
Prior to the procedures, patients were treated 
with intravenous antibiotics. The OR procedures 
were performed by 11 cardiothoracic surgeons, 
whereas the EP procedures were performed by 
5 electrophysiologists. Those who received OR 
extractions were endotracheally intubated and 
given general anesthesia. Through a median ster-
notomy, access to the heart was obtained. Patients 
were heparinized and placed on cardiopulmonary 
bypass. The leads were dissected, keeping con-
trol over vegetations when present, to prevent 
embolization. Patients undergoing EP laboratory 
procedures had a 5 Fr femoral arterial line placed 
for continuous hemodynamic monitoring as well 
as a 7 Fr femoral venous sheath for central ve-
nous access. If indicated, a temporary pacemaker 
wire was placed from the femoral or jugular area. 
Intravenous deep sedation was used in all cases. 
The distal helices of leads were retracted when 
possible and traction was applied at the beginning 
of each case. If extraction was unsuccessful with 
traction alone, the leads were then cut, sized, and 
fitted with a locking stylet (Spectranetics Inc., 
Colorado, Springs, CO). A 12 Fr, 14 Fr, or 16 Fr 
laser-powered sheath system (Spectranetics Inc., 
Colorado Springs, CO) was used depending on the 
lead size and the operator’s choice. At the end of 
the procedure, the CIED pocket was closed with 
suture material or packed and left to heal by se-
condary intention, as clinically indicated. All EP 
procedures had cardiothoracic surgical back-up 
available on site. All patients had 4 U of packed 
red blood cells on standby in case of the need for 
emergent transfusion.
The primary outcome of interest for the 
present study was total mortality at 1, 6, and 
12 months following the index procedure. Other 
procedure-related complications of lead extraction 
were also assessed using the definitions previously 
established in the consensus manuscript on lead 
extractions published in 2009 [19].
Statistical analysis
All continuous variables are presented as mean ± 
± standard deviation. All categorical variables are 
presented as absolute numbers and percentages. 
Comparison of means was performed using the 
Student’s t-test. Comparison of categorical variables 
was performed using Fisher’s exact test. Survival 
curves were constructed using the Kaplan-Meier 
method and inter-group comparison was assessed 
using the log rank test. Independent predictors 
of the time to death were examined using the 
Cox proportional hazards test. In order to correct 
for baseline differences in overall clinical status, 
the Charlson comorbidity index (CCI) was used, 
taking into account the presence and severity of 
19 comorbid conditions that impact mortality [2]. 
A 2-sided p-value ≤ 0.05 was considered statistically 
significant. All analyses were performed on PAWS 
software version 19.0 (IBM, Armonk, NY, USA).
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Results
A total of 353 patients who underwent lead 
extraction were included in this study (24 in the OR 
group and 329 in the EP group). Baseline charac-
teristics for patients receiving lead extraction via 
OR or EP techniques are shown in Table 1. Patients 
undergoing lead extraction via OR were more likely 
to have positive blood cultures, vegetations on the 
leads or other heart valves, and larger size vege-
tations. Their CCI was also significantly higher, 
indicating a worse overall clinical condition. All 
other clinical characteristics were similar between 
the two study groups.
Of the 129 patients who had positive blood cul-
tures, more than two-thirds had coagulase-negative 
or coagulase-positive Staphylococcal infections. 
As shown in Figure 1, the breakdown by type of 
bacteria recovered from blood cultures was similar 
between the two study groups.
Table 2 shows the mortality for the two study 
groups at 1, 6, and 12 months after the index pro-
cedure, as well as the rates of non-fatal procedural 
complications. Using univariate analysis, patients 
in the OR group had significantly higher total mor-
tality rates at 1, 6, and 12 months after the index 
procedure, compared to the EP group. There were 
no intraoperative deaths in either one of the two 
study groups.
The cause of death could be ascertained for 
all but 2 patients who expired within 30 days of 
the index procedure (4 deaths in OR group and 
15 deaths in EP group). Of the 4 (17%) mortalities 
in the OR group, 3 patients died of cardiogenic 
shock, while 1 patient died of a massive stroke. 
Of the 15 (5%) mortalities in the EP group, 6 died 
of severe hypotension attributed to sepsis (1 with 
confirmed septic embolization), 5 suffered multi-
-organ failure (1 patient refusing dialysis therapy 
for kidney failure), and 2 patients died as a result of 
cardiac arrest consisting of ventricular arrhythmia 
and asystole, respectively. For the remaining 2 EP 
cases, the mode of death could not be ascertained.
There were no significant differences in the 
non-fatal complication rates experienced during 
OR vs. EP extraction procedures up to 30 days 
after the index procedure. Intraoperatively, there 
were no complications reported in the OR group 
compared to 6 in the EP group (significant blood 
loss requiring transfusion: n = 3, atrial lead dis-
lodgement: n = 1, and fractured lead with retai-
ned fragment: n = 2). Non-lethal complications 
within 30 days of the index procedure were also 
examined for the two study groups. There were 
2 (8%) non-lethal complications in the OR group 
compared to 16 (5%) in the EP group. Both OR 
cases involved chest bleeding requiring surgical 
exploration. Of the 16 EP complications, 8 invol-
ved hematoma formation at the site of device 
explantation requiring evacuation in the electro-
physiology laboratory within 5 days of the index 
procedure. The other 8 complications included 
septicemia (n = 1), hemothorax (n = 1), atrial 
lead dislodgement at reimplantation (n = 1), pul-
monary embolism (n = 1), pneumothorax (n = 1), 
and intra-operative complications (n = 3) as men-
tioned above.
Table 3 shows the characteristics of patients 
who died vs. those who were alive at 1 year after 
the index procedure. Univariate predictors of death 
at 1 year after the index procedure included older 
age, the presence of positive blood cultures, pre-
sence of diabetes mellitus, presence of coronary 
artery disease, higher baseline serum creatinine le-
vel, lower baseline ejection fraction, a higher CCI, 
and performing lead extraction via OR as opposed 
to via EP approach. There was also a trend towards 
an association between female gender and death 
at 1 year after the index procedure. As expected, 
the presence of coronary disease predicted lower 
ejection fraction and the presence of diabetes 
mellitus predicted higher serum creatinine level.
The time to death in the two study groups was 
also examined. As shown in Figure 2, patients tre-
ated with EP lead extractions had significantly bet-
ter survival than those treated with OR (p = 0.002). 
After adjusting for age, gender, and CCI using 
multivariate Cox proportional hazard analysis, 
performing lead extraction through OR remained 
an independent predictor of death (hazard ratio = 
= 2.60, 95% confidence interval 1.26–5.37, p = 0.010; 
Table 4).
Discussion
Our study reveals that in cases of CIED in-
fection, lead extraction using closed-chest EP 
techniques is associated with lower mortality rates 
at 1, 6, and 12 months and better 1-year survival 
compared to the OR approach. This finding is ho-
wever tampered by the fact that the OR population 
was significantly sicker than the EP group. In this 
study, we also report on the mode of death of patients 
who expired within 30 days of the index procedure.
There is a paucity of studies in the literature 
addressing the death rate and cause of death from 
lead extraction in the case of CIED infections. Our 
study included 24 patients receiving OR for infec-
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techniques (n = 329)
P
Age [years] 68 ± 11 70 ± 14 0.54
Male 79% 75% 0.60
Implantable cardioverter-defibrillator explanted 50% 52% 0.85
Oldest lead dwell time [months] 55 ± 55 56 ± 57 0.96
QRS duration [ms] 135 ± 38 135 ± 40 0.98
Ejection fraction [%] 36 ± 15 39 ± 16 0.57
Creatinine [mg/dL] 1.9 ± 1.4 1.5 ± 1.1 0.06
Coronary artery disease 67% 65% 0.90
Diabetes 50% 37% 0.20
Positive blood culture 87% 34% < 0.001
Vegetation present on the leads 92% 19% < 0.001
Size of vegetation [cm2] 4.5 ± 2.5 1.8 ± 2.0 0.001
Need for concomitant heart surgery: 67% 0% < 0.001
Mitral valve surgery (n = 4)
Aortic valve surgery (n = 3)
Tricuspid surgery (n = 1)
Coronary bypass (n = 4)
Atrial septal defect closure (n = 4)
Prior pulmonary embolism 12% 2% 0.016
Pulmonary embolism post procedure 4% 1% 0.25
Charlson comorbidity index 3.3 ± 2.6 2.2 ± 1.8 0.006
Infection upon generator replacement 17% 29% 0.24
Lead types for defibrillator explants: 0.90
Right atrial 38% 34%
Right ventricular 46% 50%
Left ventricular 16% 16%
Lead types for pacemaker explants:
Right atrial 48% 47% 0.83
Right ventricular 52% 53%
Left ventricular 0% 0%
Use of powered laser system – 60% –
Success of all lead removal 96% 94% 1.00
Other infections: 12% 4% 0.08
Urinary infection 1 4
Pneumonia 0 3
Septic emboli 2 1
Epidural abscess 0 2
Arthritic infection 0 2
Osteomyelitis 0 1
Post-surgical antibiotic duration [days] 5.2 ± 1.0 3.2 ± 1.9 < 0.01
Complications of antibiotic therapy: 12% 4% 0.08
Acute interstitial nephritis 2 4
Altered mental status 1 0
Clostridium difficile colitis 0 5
Drug fever 0 1
Rash 0 1
Elevated liver enzymes 0 1
Renal failure 0 1
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ted CIED system and found that the mortality rate 
is about 17% at 30 days after the index procedure. 
This is in keeping with the results of a smaller 
study by Wilhelm et al. [21] examining the outco-
me of 8 patients with infected pacemaker systems 
undergoing OR in which a 12.5% 30-day mortality 
rate was reported. Camboni et al. [22] reported 
a lower rate of death 30 days after surgery (9%) in 
21 patients receiving OR. It is worth mentioning, 
however, that this latter study included a significant 
number of non-infected patients who were there-
fore less sick compared to our patient population.
Table 3. Univariate predictors of death 1 year after the index procedure.
Variable Died (n = 71) Alive (n = 281) P 
Age [years] 75 ± 12 68 ± 13 < 0.001
Gender (men) 66% 77% 0.06
Ejection fraction [%] 34 ± 14 40 ± 16 0.023
Creatinine [mg/dL] 2.0 ± 1.4 1.4 ± 1.0 < 0.001
Coronary artery disease 82% 61% 0.001
Diabetes mellitus 51% 34% 0.012
QRS width [ms] 137 ± 35 135 ± 41 0.74
Positive blood cultures or vegetations 61% 37% < 0.001
Open-thoracotomy extraction 14% 5% 0.012
Implantable cardioverter-defibrillator explanted 59% 50% 0.21
Charlson comorbidity index 3.1 ± 2.2 2.0 ± 1.7 < 0.001
Table 2. Mortality and non-lethal complication rates for the two study groups.





Deaths after 30 days 4/24 (17%) 15/329 (5%) 0.036
Deaths after 6 months 8/24 (33%) 45/329 (14%) 0.020
Deaths after 1 year 10/24 (42%) 61/329 (19%) 0.012
Non-lethal complications during procedure 0/24 (0.0%) 6/329 (2.0%) 0.99
Non-lethal complications 30 days post procedure 2/24 (8%) 22/329 (7%) 0.31
Hospital length of stay [days] 23 ± 15 12 ± 9 < 0.001
Figure 1. Bacteria recovered from blood cultures of patients undergoing lead extraction in the operating room via 
open thoracotomy (OR) (A) versus percutaneously in the electrophysiology (EP) laboratory (B). Staphylococcal infec-
tion where sensitivity data was not available is in white.
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Table 4. Cox proportional hazard predictor of death 1 year after index procedure.
P Odds ratio 95% confidence interval
 Lower Upper
Open chest (vs. closed chest) 0.010 2.60 1.26 5.37
Gender (women vs. men) 0.08 0.64 0.39 1.05
Age (1 year increment) < 0.001 1.04 1.02 1.06
Charlson comorbidity index 0.003 1.17 1.05 1.29
Figure 2. Kaplan-Meier curves showing the survival of 
patients with cardiac implantable electronic devices in-
fection after lead extraction in both the open-thoracoto-
my (OR) (open chest) and percutaneously (EP) (closed 
chest) study groups.
The mortality and morbidity associated with 
CIED system extraction for infectious indications 
using closed-chest techniques has been previously 
examined. Grammes et al. [17] reported on the fe-
asibility of explanting such infected CIED systems 
in 100 patients with documented large vegetations 
by transesophageal echocardiography. The 30- 
-day mortality in that cohort of patients was 10%, 
which is higher than the 5% rate we report in our 
present population. The difference in mortality is 
most likely attributable to the fact that our patients 
were less sick than the ones included in the study 
by Grammes et al. [17] as only 19% of our patients 
had documented vegetations.
The mode of death in patients who expired 
within 30 days of the index procedure was different 
between our two study groups. Whereas half of the 
OR patients died of cardiogenic shock presumably 
induced by the invasive surgery performed with 
general anesthesia and cardiopulmonary bypass, 
most of the EP-treated patients died of sepsis and 
multi-organ failure. These data add some insight 
into the shortcomings of each of these two treat-
ment strategies.
Limitations of the study
Our study has some limitations. First, it is 
a single-center study that may not represent the 
experience at other institutions. The presence of 
local expertise in both surgical and percutaneous 
lead extractions is a prerequisite for making cli-
nical choices at any institution and for providing 
surgical support in the event of complications or 
failure of the percutaneous approach. Second, our 
study is retrospective and may therefore inclu-
de biases, such as performance of concomitant 
surgeries in the open-chest group that could not 
be eliminated despite the statistical adjustment 
of multivariate analyses. In addition, the size of 
the two study groups was very different, which 
may introduce further bias. We have, however, 
included all patients undergoing lead extraction 
for infectious indications to minimize potential 
sources of bias. Therefore, the numbers included 
in each of the study group represent the overall 
clinical practice at our institution. Multivariate 
models were also used to adjust for unbalanced 
variables between the study groups. Lastly, becau-
se of incomplete documentation in the operative 
and original implantation notes, the fixation type 
of extracted leads and the number of coils on ex-
tracted defibrillator leads could not be ascertained 
in this study.
Conclusions
In conclusion, infected CIED patients under-
going open-chest lead extraction are sicker and 
have higher mortality rates compared to those 
undergoing percutaneous extraction. Randomized, 
prospective data are needed to determine whether 
the procedural strategy for lead extraction can im-
pact the outcome of CIED infected patients.
www.cardiologyjournal.org 73
Divyang Patel et al., Extraction of infected CIED leads
Conflict of interest: Evan Adelstein — Research 
grants from SJM, MDT; Samir Saba — Research 
grants from SJM, MDT, BSC.
References
1. Moss AJ, Zareba W, Hall WJ et al.; Multicenter Automatic Defi-
brillator Implantation Trial II Investigators. Prophylactic implan-
tation of a defibrillator in patients with myocardial infarction and 
reduced ejection fraction. N Engl J Med, 2002; 346: 877–883.
2. Buxton A, Lee K, DiCarlo L, Gold M et al. Electrophysiologic 
testing to identify patients with coronary artery disease who are 
at risk for sudden death. N Engl J Med, 2000; 342: 1937–1945.
3. The Antiarrhythmics versus Implantable Defibrillators (AVID) 
Investigators. A comparison of antiarrhythmic-drug therapy with 
implantable defibrillators in patients resuscitated from near-fatal 
ventricular arrhythmias. N Engl J Med, 1997; 337: 1576–1583.
4. Epstein AE, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 
2008 Guidelines for Device-Based Therapy of Cardiac Rhythm 
Abnormalities: a report of the American College of Cardiology/ 
/American Heart Association Task Force on Practice Guidelines 
(Writing Committee to Revise the ACC/AHA/NASPE 2002 Gu-
ideline Update for Implantation of Cardiac Pacemakers and An-
tiarrhythmia Devices) developed in collaboration with the Ame-
rican Association for Thoracic Surgery and Society of Thoracic 
Surgeons. J Am Coll Cardiol, 2008; 51: e1–e62.
5. Zhan C, Baine W, Sedrakyan A, Steiner C. Cardiac device implan-
tation in the United States from 1997 through 2004: A population-
-based analysis. J Gen Intern Med, 2008; 23: 13–19.
6. Peterson PN, Daugherty SL, Wang Y et al.; the National Cardio-
vascular Data Registry. Gender differences in procedure-related 
adverse events in patients receiving implantable cardioverter-
-defibrillator therapy. Circulation, 2009; 119: 1078–1084.
7. Cabell CH, Heidenreich PA, Chu VH et al. Increasing rates of car-
diac device infections among Medicare beneficiaries: 1990–1999. 
Am Heart J, 2004; 147: 582–586.
8. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm ma-
nagement device infections in the United States: 1996 through 
2003. J Am Coll Cardiol, 2006; 48: 590–591.
9. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascu-
lar implantable electronic device infections in the United States: 
Temporal trends and causative insights. Pacing Clin Electrophy-
siol, 2010; 33: 414–419.  
10. Chua JD, Wilkoff BL, Lee I, Juratli N, Longworth DL, Gordon SM. 
Diagnosis and management of infections involving implantable 
electrophysiologic cardiac devices. Ann Intern Med, 2000; 133: 
604–608.
11. Love CJ, Wilkoff BL, Byrd CL et al. Recommendations for extra-
ction of chronically implanted transvenous pacing and defibrillator 
leads: Indications, facilities, training. Pacing Clin Electrophysiol, 
2000; 23: 544–551.
12. Sohail MR, Uslan DZ, Khan AH et al. Management and outcome 
of permanent and implantable cardioverter-defibrillator infec-
tions. J Am Coll Cardiol, 2007; 49: 1851–1859.
13. Deharo JC, Quatre A, Mancini J et al. Long-term outcomes fol-
lowing infection of cardiac implantable electronic devices: A pro-
spective matched cohort study. Heart, 2012; 98: 9724–9731.
14. Chamis AL, Peterson GE, Cabell CH et al. Staphylococcus aureus 
bacteremia in patients with permanent pacemakers or implantab-
le cardioverter defibrillators. Circulation, 2001; 104: 1029–1033. 
15. Chiu WS, Nguyen D. Pacemaker lead extraction in pacemaker 
endocarditis with lead vegetation: usefulness of transesophageal 
echocardiography. Can J Cardiol, 1998; 14: 87–89. 
16. Meier-Ewert H, Gray ME, John R. Endocardial pacemaker or de-
fibrillator leads with infected vegetations: A single-center expe-
rience and consequences of transvenous extraction. Am Heart J, 
2003; 146: 339–344.
17. Grammes J, Schulze C, Al-Bataineh M et al. Percutaneous pace-
maker and implantable cardioverter-defibrillator lead extraction 
in 100 patients with intracardiac vegetations defined by transe-
sophageal echocardiogram. J Am Coll Cardiol, 2010; 55: 886–894. 
18. Nguyen KT, Neese P, Kessler DJ. Successful laser-assisted 
percutaneous extraction of four pacemaker leads associated 
with large vegetations. Pacing Clin Electrophysiol, 2000; 23: 
1260–1262.
19. Wilkoff BL, Love CJ, Byrd CL et al. Heart Rhythm Society; 
American Heart Association. Transvenous lead extraction: Heart 
Rhythm Society expert consensus on facilities, training, indica-
tions, and patient management: This document was endorsed by 
the American Heart Association (AHA). Heart Rhythm, 2009; 6: 
1085–1104.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method 
of classifying prognostic comorbidity in longitudinal studies: de-
velopment and validation. J Chronic Dis, 1987; 40: 373–383.
21. Wilhelm MJ, Schmid C, Hammel D et al. Cardiac pacemaker 
infection: surgical management with and without extracorporal 
circulation. Ann Thorac Surgery, 1997; 64: 1707–1712.
22. Camboni D, Wollmann CG, Loher A, Gradaus R, Scheld HH, 
Schmid C. Explantation of implantable defibrillator leads using 
open heart surgery or percutaneous techniques. Ann Thorac 
Surg, 2008; 85: 50–55.
74 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 1
